Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
This protocol is for subjects with pulmonary arterial hypertension and is the first of 3
 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective
 Assessment of Adding Sildenafil (SR-PAAS) program.
Inclusion Criteria:

 -  Current diagnosis of symptomatic pulmonary arterial hypertension (PAH) classified by
 one of the following: idiopathic arterial hypertension (IPAH), primary pulmonary
 hypertension (PPH), familial pulmonary arterial hypertension (FPAH) or pulmonary
 arterial hypertension (PAH) associated with connective tissue diseases. Has WHO
 functional class III symptoms.

 Exclusion Criteria:

 -  Previous exposure to an endothelin receptor antagonist (ETRA) such as sitaxsentan,
 bosentan or ambrisentan.